Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

US Patent 11352405 · Granted Jun 7, 2022

Estimated economic value: $27,001,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polymer nanoparticle compositions for in vivo expression of polypeptides2025
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Selective glucagon receptor agonists comprising a chelating moiety for imaging p2021
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Exendin-4 derivatives as dual GLP1/glucagon agonists2020